Oppenheimer Weighs in on PLx Pharma Inc.’s FY2022 Earnings (NASDAQ:PLXP)

PLx Pharma Inc. (NASDAQ:PLXPGet Rating) – Equities research analysts at Oppenheimer boosted their FY2022 earnings estimates for PLx Pharma in a research report issued on Wednesday, November 16th. Oppenheimer analyst L. Gershell now anticipates that the biotechnology company will post earnings per share of ($1.81) for the year, up from their previous estimate of ($2.04). Oppenheimer has a “Market Perform” rating on the stock. The consensus estimate for PLx Pharma’s current full-year earnings is ($2.04) per share. Oppenheimer also issued estimates for PLx Pharma’s Q4 2022 earnings at ($0.33) EPS, Q1 2023 earnings at ($0.35) EPS, Q2 2023 earnings at ($0.36) EPS, Q4 2023 earnings at ($0.35) EPS and FY2023 earnings at ($1.41) EPS.

Separately, JMP Securities cut shares of PLx Pharma from an “outperform” rating to a “market perform” rating in a research report on Monday, August 15th.

PLx Pharma Trading Down 4.1 %

PLx Pharma stock opened at $0.33 on Friday. PLx Pharma has a 12-month low of $0.30 and a 12-month high of $10.70. The stock has a market cap of $9.70 million, a P/E ratio of -0.18 and a beta of 3.73. The company has a 50-day moving average price of $0.57 and a 200 day moving average price of $1.53.

Institutional Investors Weigh In On PLx Pharma

A number of institutional investors have recently made changes to their positions in the stock. University of Texas Texas AM Investment Managment Co. increased its position in shares of PLx Pharma by 100.0% during the third quarter. University of Texas Texas AM Investment Managment Co. now owns 125,346 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 62,673 shares during the last quarter. O Brien Greene & Co. Inc increased its position in shares of PLx Pharma by 200.0% during the third quarter. O Brien Greene & Co. Inc now owns 67,020 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 44,680 shares during the last quarter. Green Square Capital Advisors LLC increased its position in shares of PLx Pharma by 1,830.0% during the third quarter. Green Square Capital Advisors LLC now owns 193,000 shares of the biotechnology company’s stock valued at $125,000 after acquiring an additional 183,000 shares during the last quarter. Shufro Rose & Co. LLC increased its position in shares of PLx Pharma by 44.5% during the third quarter. Shufro Rose & Co. LLC now owns 82,100 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 25,300 shares during the last quarter. Finally, Occudo Quantitative Strategies LP increased its position in shares of PLx Pharma by 171.7% during the second quarter. Occudo Quantitative Strategies LP now owns 29,301 shares of the biotechnology company’s stock valued at $71,000 after acquiring an additional 18,515 shares during the last quarter. 27.73% of the stock is currently owned by institutional investors and hedge funds.

About PLx Pharma

(Get Rating)

PLx Pharma Inc operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules.

Further Reading

Earnings History and Estimates for PLx Pharma (NASDAQ:PLXP)

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.